Predicting Significant Liver Fibrosis in Chronic Hepatitis B
Author Information
Author(s): Seto Wai-Kay, Lee Chun-Fan, Lai Ching-Lung, Ip Philip P. C., Fong Daniel Yee-Tak, Fung James, Wong Danny Ka-Ho, Yuen Man-Fung
Primary Institution: Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong
Hypothesis
Can a predictive model using routinely available clinical parameters accurately predict significant fibrosis in chronic hepatitis B patients?
Conclusion
The PAPAS index can predict and exclude significant fibrosis, potentially reducing the need for liver biopsy in chronic hepatitis B patients.
Supporting Evidence
- The PAPAS index achieved an AUROC of 0.776 for predicting significant fibrosis.
- The negative predictive value of the PAPAS index was 88.4%.
- 67.5% of liver biopsies could be avoided for patients with ALT <2×ULN using the PAPAS index.
Takeaway
Doctors created a new way to tell if people with chronic hepatitis B have serious liver damage without needing a painful liver biopsy.
Methodology
The study involved 237 treatment-naïve chronic hepatitis B patients who underwent liver biopsy, with data analyzed using a predictive model based on 12 clinical parameters.
Potential Biases
The study may be biased towards a high negative predictive value due to the patient demographics.
Limitations
The study was limited to Chinese patients and may not be applicable to other populations; external validation is needed.
Participant Demographics
The median age was 38.2 years, with 67.2% male and 41.3% HBeAg-positive patients.
Statistical Information
P-Value
0.270
Confidence Interval
0.694–0.854
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website